Advaxis das sieht gut..

Seite 1 von 1
neuester Beitrag:  06.06.15 12:36
eröffnet am: 13.01.14 10:43 von: Bäcker33 Anzahl Beiträge: 25
neuester Beitrag: 06.06.15 12:36 von: fbo|228862719 Leser gesamt: 5609
davon Heute: 2
bewertet mit 2 Sternen

13.01.14 10:43 #1 Advaxis das sieht gut..
ariva.de  
13.01.14 10:50 #2 Chart sie sehr gut aus...
Gibt es weitere News?  
13.01.14 10:56 #3 hier besser
13.01.14 11:04 #4 Advaxis to Present
Advaxis to Present at Biotech Showcase™ 2014 in San Francisco

By Business Wire,  January 08, 2014, 07:45:00 AM EDTVote upPRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that the Company will present at the Biotech Showcase™ 2014 Conference being held at the Parc 55 Wyndham San Francisco Union Square Hotel in San Francisco, CA.Read more: http://www.nasdaq.com/press-release/...o-20140108-00168#ixzz2qGsM7AmT  
13.01.14 11:16 #5 seit oktober
kommen die umsätze auch in gang  
13.01.14 18:22 #7 so
ADXS Basic Chart | Advaxis, Inc. Stock - Yahoo! Finance
Access the chart for Advaxis, Inc. (ADXS) in line, bar or candlestick type. Customize the date range from 1 day, 5-day, 1-month, 3-month, 5-month or more. Perform chart performance comparison with other stocks or market indices.
4, 36 ausbruch... mal schaun ob sie es hält  
14.01.14 07:44 #8 stark
.gegen den markt gestern  
14.01.14 14:58 #9 200
15.01.14 14:34 #10 schaffen
wir die 5 heute ?  
15.01.14 15:10 #11 adxs
15.01.14 18:32 #12 so
ADXS Technical Analysis | Advaxis, Inc. Stock - Yahoo! Finance
Get the chart for Advaxis, Inc. (ADXS) and see various technical analysis indicators including MACD, MFI, ROC, RSI, Slow Stoch, Fast Stoch and overlays such as bollinger bands, parabolic SAR, moving average and EMA.
200 line bei 5, 16 geknackt  
16.01.14 14:25 #13 bye
rating  
21.01.14 13:42 #14 news
Advaxis Announces First Patient Dosed in Phase 1/2 Head and Neck Cancer Study
By Business Wire,  January 21, 2014, 07:30:00 AM ED


Read more: http://www.nasdaq.com/press-release/...y-20140121-00243#ixzz2r2ICUw4g  
22.01.14 15:57 #15 news
23.01.14 15:26 #16 seek
Advaxis, Inc. (ADXS): Advaxis And Inovio Race For First Cervical Cancer Immunotherapy - Seeking Alpha
Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks
 
26.01.14 11:06 #17 Key Partnerships
20.03.14 10:31 #18 könnte heut kleines Stück up gehen...
...nach dem gestern nachbörslich gemeldeten Pet-Deal...
die Vorbörse wird ja schonmal den Weg zeigen:)  

Bewertung:

20.03.14 10:48 #19 Ne Menge Geld kommt da rein für so eine...
...noch kleine Company...ausserdem zeigt es das Potential für weitere
License Verträge:

KANSAS CITY, Kan., and PRINCETON, N.J., March 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.  Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis.  Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.

Under the agreement, Aratana made a one-time upfront payment to Advaxis of $1 million and an additional $1.5 million equity investment in Advaxis common stock and warrants.  Aratana agreed to pay up to an additional $6 million in clinical and regulatory milestones for each of the four products, assuming approvals in both cats and dogs in both United States and the European Union.  In addition, Aratana agreed to pay up to $28.5 million in commercial milestones.  Upon regulatory approval and commercialization of the immunotherapies, Aratana agreed to pay Advaxis a tiered royalty ranging from mid-single digit to 10% on net sales.
 

Bewertung:

20.03.14 10:51 #20 im best case 37 mio...
...+ Royalties on net sales!
bei einer Marketcap. von 68 mio.$ von Advaxis ist das schon eine Hausnummer!  

Bewertung:

20.03.14 15:21 #21 hab alles verkauft bei 5 $...
...Aktie, welche bei so einer Meldung ins Minus rutscht stinkt zum Himmel..
ob geshortet, manipuliert oder kein Interesse ist mir wurscht...  

Bewertung:

31.03.14 14:15 #22 millemax
Gut gemacht. Der jetzige Preis lädt aber zum Wiedereinstieg ein. biotech  
03.03.15 17:51 #24 das is
doch mal ne gute jahres perf. oder?  
06.06.15 12:36 #25 kann man so sagen :)
Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen:    


Bitte warten...